February 28th 2024
Ropeginterferon alfa is now a recommended first-line treatment for patients with polycythemia vera, according to the National Comprehensive Cancer Network’s updated guidelines.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board